Latest News

View All
Nov 1, 2018

Gamida Cell Announces New Translational Data for NiCord® to be Presented at ASH 2018 Annual Meeting

Read More
Sep 18, 2018

Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman

Read More
Aug 6, 2018

Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications

Read More
Jul 23, 2018

Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access

Read More
Jun 18, 2018

Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma

Read More
Apr 30, 2018

Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting

Read More
Apr 26, 2018

Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing

Read More
Mar 19, 2018

Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting

Read More
Mar 16, 2018

Gamida Cell to Present at Upcoming Investor Conferences

Read More
Mar 15, 2018

Gamida Cell Appoints Shai Lankry as Chief Financial Officer

Read More
Feb 20, 2018

Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings

Read More
Jan 16, 2018

Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma

Read More
Dec 11, 2017

Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

Read More
Nov 20, 2017

Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer

Read More
Nov 1, 2017

Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting

Read More
Sep 26, 2017

Gamida Cell World Cord Blood Day Conference, November 15, 2017

Read More
Aug 21, 2017

Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS

Read More
Jul 20, 2017

Gamida Cell Announces $3.5 Million Grant from the Israeli Government

Read More
Jul 10, 2017

Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer

Read More
Jun 19, 2017

Gamida Cell Announces $40 Million Private Financing

Read More

News Spotlight

Oct 26, 2018

Gamida Cell Announces Pricing of Initial Public Offering

Read More

Committed to changing treatment paradigms

We are focused on developing novel cell therapies as a potentially curative approach for patients with serious medical conditions who have limited treatment options.

Learn more about the cell therapies we are developing.